Shine to commercialise Lu-177 production

22 June 2021

US-based Shine Medical Technologies on 14 June signed a "multiyear" partnership with the University of Missouri Research Reactor (MURR) in Columbia, Missouri, to produce lutetium-177 (Lu-177), a drug that shows promise in targeting and treating certain late-stage cancers. This will allow Shine to move forward in commercialisation of Lu-177, the company said.

Shine spokesman Rod Hise said the company has been producing Lu-177 on a "small scale" at its nuclear particle accelerator testing facility on Janesville's south side. That work is being done in tandem with the ongoing build-out of a 45,000-square-foot production facility that is slated for completion and commercialisation by 2022.

Shine initially received federal regulatory approval to build its future Janesville plant as a production facility to make the bone and tissue illuminating agent molybdenum-99, but the company also has been working toward production of cancer drugs, including Lu-177. 

Hise said when the Janesville production facility is completed, its array of multiple nuclear particle accelerators will be capable of producing 300,000 doses of Lu-177 a year.

The contract with MURR covers irradiation of ytterbium-176, the starting material for the production of Lu-177. “MURR’s experienced team and reliable reactor make its irradiation services invaluable to Shine as we commercialise our Lu-177,” said Katrina Pitas, vice president and general manager of Shine Therapeutics. “MURR’s high neutron flux will help us produce all the non-carrier-added Lu-177 we need to serve our rapidly growing customer base, treating a wide variety of cancers.”

Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.